RecruitingNot ApplicableNCT04798898

Improving Survival of COlorectal LIver Metastases by RFA-mediated Immunostimulation


Sponsor

University of Aarhus

Enrollment

200 participants

Start Date

Nov 14, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

To examine radio frequency ablation as a treatment supplement to stimulate immunogenicity and improve survival for patients undergoing curative-intent surgery for colorectal liver metastases.


Eligibility

Min Age: 18 YearsMax Age: 99 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether adding radiofrequency ablation (using heat to destroy tumor tissue) before standard liver surgery for colorectal cancer that has spread to the liver can help stimulate the immune system to fight remaining cancer cells, potentially improving survival. **You may be eligible if...** - You have colorectal cancer that has spread to your liver and are scheduled for surgery to remove it - At least one liver tumor is 3 cm or larger - You are in good general health (performance status 0-1) **You may NOT be eligible if...** - You have liver cirrhosis (severe liver scarring) - Your cancer has spread to other areas of the body that cannot be treated with curative intent - You have had another cancer within the past 5 years Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICERFA (radiofrequency ablation)

Preoperative RFA-induced partial necrosis of the liver metastasis


Locations(1)

Aarhus University Hospital, Department of Surgery

Aarhus, Denmark

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04798898


Related Trials